BRCA1 and cancer: The CX‐5461 properties unravelled in this study made it a good candidate for further testing in a phase 1 clinical trial in cancer patients carrying DNA repair defects, including BRCA1/2 mutations (https://clinicaltrials.gov/show/NCT02719977).